SLC6A12-AS1

Across TCGA pan-cancer cohorts, SLC6A12-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SLC6A12-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC6A12-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC6A12-AS1 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, HNSC, and UCEC are the cancer types where SLC6A12-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A12-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	III,IV	−1.450	<.001	11	view →
HNSC	All	III,IV	+0.069	.005	8	view →
UCEC	All	All	−0.534	<.001	6	view →
KIRP	All	All	−0.264	.021	5	view →
BRCA	Female	All	−0.062	.005	5	view →
KICH	All	II,III,IV	−0.399	.001	4	view →
LIHC	All	All	+0.081	.002	4	view →
LUAD	All	III,IV	−0.052	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SLC6A12-AS1–THCA

Open the THCA breakdown →